Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases.
Bluejay Therapeutics has raised $182.0M in total funding. The most recent round was Series C. The last funding was announced in May 2024.
Bluejay Therapeutics's investors include Wellington Management, RA Capital Management, Novo Holdings, RiverVest, Frazier Life Sciences.
Bluejay Therapeutics is headquartered in San Mateo, United States.
Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases.
Bluejay Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Bluejay Therapeutics — Funding & Investors." VCBacked, May 9, 2024, https://www.vcbacked.co/company/bluejay-therapeutics. Accessed July 19, 2026.
VCBacked. (2024). Bluejay Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/bluejay-therapeutics
{{cite web |title=Bluejay Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/bluejay-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated